title: Ozurdex(®) reduces the retinal thickness in radiation maculopathy refractory to bevacizumab.
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Lisa
authors.initials: L
authors.lastname: Tarmann
authors.forename: Gerald
authors.initials: G
authors.lastname: Langmann
authors.forename: Christoph
authors.initials: C
authors.lastname: Mayer
authors.forename: Martin
authors.initials: M
authors.lastname: Weger
authors.forename: Anton
authors.initials: A
authors.lastname: Haas
authors.forename: Werner
authors.initials: W
authors.lastname: Wackernagel
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008545:Melanoma / Q000532:radiotherapy; D008875:Middle Aged; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D012160:Retina / Q000473:pathology / Q000528:radiation effects*; D012429:Ruthenium Radioisotopes / Q000009:adverse effects*; D017211:Treatment Failure; D014604:Uveal Neoplasms / Q000532:radiotherapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D000098943:Uveal Melanoma
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004343:Drug Implants; D005938:Glucocorticoids; D012429:Ruthenium Radioisotopes; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D003907:Dexamethasone